In early April, Kazakh Invest and Polpharma Group signed a memorandum on the development of pharmaceutical manufacturing in Kazakhstan. In an interview with Kursiv.media, Markus Sieger, CEO of Polpharma Group, explained why this document is so important for both parties and what Polpharma Group aims to achieve in Kazakhstan.
– Polpharma Group has signed a new memorandum with Kazakh Invest. What are the main objectives of the document?
– First of all, we are very pleased that the government of Kazakhstan supports our intention to help patients within the country and across the Central Asian region. As you know, Polpharma...